Zydus to Launch Single Pen for Adjustable Semaglutide Doses

Key Highlights:

• Zydus is creating a single-pen semaglutide device for diabetes and obesity, with global rollout plans.
• Its novel delivery system aims to boost patient adherence and cut costs.
• Zydus eyes a "day 1" India launch and seeks partners for emerging markets.

Zydus Lifesciences is developing a new semaglutide formulation for diabetes and obesity, two rapidly growing chronic conditions that are becoming increasingly debilitating.

Rather than requiring patients to use various devices for single-dose shots, Zydus has developed a new one-pen system that will allow users to select from several different dose strengths in one unit, making use easier

Also read: How Organic Synthesis is Accelerating Drug Discovery in Pharma

"Our current strategy for semaglutide, both for India and the developing markets, is that we have a novel formulation for semaglutide that we are going to commercialise both in India and the other markets," Zydus MD Sharvil Patel told investors in an earnings call.

He said the company is gearing up to catch the first wave of launch in India. "And we are on track for day 1 launch in India," said Patel.

Zydus is also looking to extend the product into other emerging markets, and is exploring licensing opportunities as well. Patel noted that there are several companies interested in co-marketing opportunities with Zydus. Although the semaglutide formulation was developed internally, the device technology was from an undisclosed partner, and has been patented already.